Cargando…

Immune Modulation and Cytomegalovirus Reactivation in Sepsis-induced Immunosuppression: A Pilot Study

INTRODUCTION: Sepsis is a life-threatening condition caused due to dysregulated immune response to an infection and progressive immunosuppression. Reactivation of cytomegalovirus (CMV) occurs frequently in sepsis and is found associated with adverse outcomes. The study objective was to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambe, Gaurav, Mansukhani, Dia, Khodaiji, Shanaz, Shetty, Anjali, Rodrigues, Camilla, Kapadia, Farhad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Jaypee Brothers Medical Publishers 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783232/
https://www.ncbi.nlm.nih.gov/pubmed/35110845
http://dx.doi.org/10.5005/jp-journals-10071-24079
_version_ 1784638488616894464
author Lambe, Gaurav
Mansukhani, Dia
Khodaiji, Shanaz
Shetty, Anjali
Rodrigues, Camilla
Kapadia, Farhad
author_facet Lambe, Gaurav
Mansukhani, Dia
Khodaiji, Shanaz
Shetty, Anjali
Rodrigues, Camilla
Kapadia, Farhad
author_sort Lambe, Gaurav
collection PubMed
description INTRODUCTION: Sepsis is a life-threatening condition caused due to dysregulated immune response to an infection and progressive immunosuppression. Reactivation of cytomegalovirus (CMV) occurs frequently in sepsis and is found associated with adverse outcomes. The study objective was to evaluate the association between incidence of CMV reactivation and immune alteration in sepsis-induced immunosuppression in patients with prolonged sepsis. PATIENTS AND METHODS: Patients admitted to intensive care unit (ICU), with severe sepsis and CMV immunoglobulin G (IgG) seropositivity, were prospectively enrolled. Other manifest immune suppression causes were excluded. Samples were collected on enrolment and further once a week until day 21 or death/discharge. CMV viral load was quantified using qPCR. Lymphocyte subset analysis (CD3+, CD4+, CD8+, CD19+, CD16+/CD56+, and CD25+CD127− regulatory T cells), human leukocyte antigen-DR isotype (HLA-DR) expression on monocytes, programmed death-1 (PD-1) expression on T lymphocytes, and proinflammatory (interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ)), anti-inflammatory cytokines levels (IL-2, IL-4, and IL-10) were analyzed by flow cytometry as markers for immunosuppression. RESULTS: A total of 25 CMV IgG-positive patients and 11 healthy controls were included. CMV reactivation occurred in 20 patients. Patients with CMV reactivation had T-cell lymphopenia. PD-1 expression on CD4+ and CD8+ T cells was markedly elevated (p <0.02) in CMV-reactivated patients compared to nonreactivated patients. HLA-DR expression was significantly low on monocytes in all septic patients (p <0.01) compared to healthy controls. IL-6 levels showed elevation at day 7, whereas IL-10 was found to be significantly higher from day 0 in CMV-reactivated group. CONCLUSION: Our study concluded that immune suppression markers and cytokine levels in patients with severe sepsis were found to be significantly associated with the incidence of CMV reactivation. HOW TO CITE THIS ARTICLE: Lambe G, Mansukhani D, Khodaiji S, Shetty A, Rodrigues C, Kapadia F. Immune Modulation and Cytomegalovirus Reactivation in Sepsis-induced Immunosuppression: A Pilot Study. Indian J Crit Care Med 2022;26(1):53–61.
format Online
Article
Text
id pubmed-8783232
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Jaypee Brothers Medical Publishers
record_format MEDLINE/PubMed
spelling pubmed-87832322022-02-01 Immune Modulation and Cytomegalovirus Reactivation in Sepsis-induced Immunosuppression: A Pilot Study Lambe, Gaurav Mansukhani, Dia Khodaiji, Shanaz Shetty, Anjali Rodrigues, Camilla Kapadia, Farhad Indian J Crit Care Med Original Article INTRODUCTION: Sepsis is a life-threatening condition caused due to dysregulated immune response to an infection and progressive immunosuppression. Reactivation of cytomegalovirus (CMV) occurs frequently in sepsis and is found associated with adverse outcomes. The study objective was to evaluate the association between incidence of CMV reactivation and immune alteration in sepsis-induced immunosuppression in patients with prolonged sepsis. PATIENTS AND METHODS: Patients admitted to intensive care unit (ICU), with severe sepsis and CMV immunoglobulin G (IgG) seropositivity, were prospectively enrolled. Other manifest immune suppression causes were excluded. Samples were collected on enrolment and further once a week until day 21 or death/discharge. CMV viral load was quantified using qPCR. Lymphocyte subset analysis (CD3+, CD4+, CD8+, CD19+, CD16+/CD56+, and CD25+CD127− regulatory T cells), human leukocyte antigen-DR isotype (HLA-DR) expression on monocytes, programmed death-1 (PD-1) expression on T lymphocytes, and proinflammatory (interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ)), anti-inflammatory cytokines levels (IL-2, IL-4, and IL-10) were analyzed by flow cytometry as markers for immunosuppression. RESULTS: A total of 25 CMV IgG-positive patients and 11 healthy controls were included. CMV reactivation occurred in 20 patients. Patients with CMV reactivation had T-cell lymphopenia. PD-1 expression on CD4+ and CD8+ T cells was markedly elevated (p <0.02) in CMV-reactivated patients compared to nonreactivated patients. HLA-DR expression was significantly low on monocytes in all septic patients (p <0.01) compared to healthy controls. IL-6 levels showed elevation at day 7, whereas IL-10 was found to be significantly higher from day 0 in CMV-reactivated group. CONCLUSION: Our study concluded that immune suppression markers and cytokine levels in patients with severe sepsis were found to be significantly associated with the incidence of CMV reactivation. HOW TO CITE THIS ARTICLE: Lambe G, Mansukhani D, Khodaiji S, Shetty A, Rodrigues C, Kapadia F. Immune Modulation and Cytomegalovirus Reactivation in Sepsis-induced Immunosuppression: A Pilot Study. Indian J Crit Care Med 2022;26(1):53–61. Jaypee Brothers Medical Publishers 2022-01 /pmc/articles/PMC8783232/ /pubmed/35110845 http://dx.doi.org/10.5005/jp-journals-10071-24079 Text en Copyright © 2022; The Author(s). https://creativecommons.org/licenses/by-nc/4.0/© The Author(s). 2022 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Article
Lambe, Gaurav
Mansukhani, Dia
Khodaiji, Shanaz
Shetty, Anjali
Rodrigues, Camilla
Kapadia, Farhad
Immune Modulation and Cytomegalovirus Reactivation in Sepsis-induced Immunosuppression: A Pilot Study
title Immune Modulation and Cytomegalovirus Reactivation in Sepsis-induced Immunosuppression: A Pilot Study
title_full Immune Modulation and Cytomegalovirus Reactivation in Sepsis-induced Immunosuppression: A Pilot Study
title_fullStr Immune Modulation and Cytomegalovirus Reactivation in Sepsis-induced Immunosuppression: A Pilot Study
title_full_unstemmed Immune Modulation and Cytomegalovirus Reactivation in Sepsis-induced Immunosuppression: A Pilot Study
title_short Immune Modulation and Cytomegalovirus Reactivation in Sepsis-induced Immunosuppression: A Pilot Study
title_sort immune modulation and cytomegalovirus reactivation in sepsis-induced immunosuppression: a pilot study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783232/
https://www.ncbi.nlm.nih.gov/pubmed/35110845
http://dx.doi.org/10.5005/jp-journals-10071-24079
work_keys_str_mv AT lambegaurav immunemodulationandcytomegalovirusreactivationinsepsisinducedimmunosuppressionapilotstudy
AT mansukhanidia immunemodulationandcytomegalovirusreactivationinsepsisinducedimmunosuppressionapilotstudy
AT khodaijishanaz immunemodulationandcytomegalovirusreactivationinsepsisinducedimmunosuppressionapilotstudy
AT shettyanjali immunemodulationandcytomegalovirusreactivationinsepsisinducedimmunosuppressionapilotstudy
AT rodriguescamilla immunemodulationandcytomegalovirusreactivationinsepsisinducedimmunosuppressionapilotstudy
AT kapadiafarhad immunemodulationandcytomegalovirusreactivationinsepsisinducedimmunosuppressionapilotstudy